UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2020
or
 
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
 
Commission file number          001-38299
 
 
cbdMD, INC.
(Exact Name of Registrant as Specified in its Charter)
 
North Carolina
 
47-3414576
State or Other Jurisdiction of
Incorporation or Organization
 
I.R.S. Employer Identification No.
 
 
 
8845 Red Oak Blvd, Charlotte, NC
 
28217
Address of Principal Executive Offices
 
Zip Code
 
704-445-3060
Registrant’s Telephone Number, Including Area Code
 
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
common
YCBD
NYSE American
8% Series A Cumulative Convertible Preferred Stock
YCBD PR A
NYSE American
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes      No ☐
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer 
Smaller reporting company 
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐    No  
 
APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
52,105,648 shares of common stock are issued and outstanding as of August 01, 2020.

 
 
 
TABLE OF CONTENTS
 
 
 
OTHER PERTINENT INFORMATION
 
Unless the context otherwise indicates, when used in this report, the terms the “Company,” “cbdMD, “we,” “us, “our” and similar terms refer to cbdMD, Inc., a North Carolina corporation formerly known as Level Brands, Inc., and our subsidiaries CBD Industries LLC, a North Carolina limited liability company formerly known as cbdMD LLC, which we refer to as “CBDI”, Paw CBD, Inc., a recently formed North Carolina corporation which we refer to as “Paw CBD”. In addition, "fiscal 2019" refers to the year ended September 30, 2019, “fiscal 2020” refers to the year ended September 30, 2020, and "third quarter of 2019" refers to the three months ended June 30, 2019 and "third quarter of 2020" refers to the three months ended June 30, 2020.
 
We maintain a corporate website at www.cbdmd.com. The information contained on our corporate website and our various social media platforms are not part of this report.
 
 
 
 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
 
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “aim,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. Forward-looking statements include, but are not limited to, statements about:
 
our history of losses;
the impact and the unknown related to the COVID-19 pandemic;
the impact of changes in the fair value of our contingent liabilities associated with the Earnout Shares;
the possible need to raise additional capital in the future;
dilution to our shareholders upon the issuance of the Earnout Shares;
changes in state laws, costs associated with compliance with applicable laws and potential uncertain changes to regulations impacting our industry;
risks associated with any future failure to satisfy the NYSE American LLC continued listing standards;
terms of and provisions of our 8.0% Series A Cumulative Convertible Preferred Stock;
risks associated with developing a liquid market for our 8.0% Series A Cumulative Convertible Preferred Stock and possible future volatility in its trading price and the trading price of our common stock;
risks associated with our status as an emerging growth company;
risks associated with control by our executive officers, directors and affiliates;
risks associated with unfavorable research reports;
the lack of long-term contracts for the purchase of our products;
our ability to protect our intellectual property;
additional operational risks associated with our CBD business;
dilution to our shareholders from the issuance of additional shares of common stock by us, the conversion of shares of our 8.0% Series A Cumulative Convertible Preferred Stock and/or the exercise of outstanding options and warrants; and
risks associated with our articles of incorporation, bylaws and North Carolina law.
 
Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements and readers should carefully review this report in its entirety, including the risks described in Part II, Item 1A. Risk Factors appearing later in this report, Part I, Item 1A. - Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 30, 2019 as filed with the Securities and Exchange Commission (the “SEC”) on December 18, 2019, as amended on January 24, 2020 (collectively, the "2019 10-K"), as well as our other filings with the SEC. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
 
 
3
 
 
PART 1 - FINANCIAL INFORMATION
 
ITEM 1. 
FINANCIAL STATEMENTS.
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JUNE 30, 2020 AND SEPTEMBER 30, 2019
 
 
 
 
(Unaudited)
 
 
 
 
 
 
June 30,
 
 
September 30,
 
 
 
2020
 
 
2019
 
Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
  Cash and cash equivalents
 $15,006,319 
 $4,689,966 
  Accounts receivable
  715,205 
  1,425,697 
  Accounts receivable other
  - 
  160,137 
  Accounts receivable – discontinued operations
  700,884 
  1,080,000 
  Marketable securities
  52,527 
  198,538 
  Investment other securities
  - 
  600,000 
  Deposits
  - 
  6,850 
  Merchant reserve
  - 
  519,569 
  Inventory
  6,397,326 
  4,301,586 
  Inventory prepaid
  281,885 
  903,458 
  Deferred issuance costs
  - 
  93,954 
  Prepaid software
  - 
  206,587 
  Prepaid equipment deposits
  201,698 
  868,589 
  Prepaid expenses and other current assets
  755,906 
  688,104 
Total current assets
  24,111,750 
  15,743,035 
 
    
    
Other assets:
    
    
  Property and equipment, net
  3,067,909 
  1,715,557 
  Operating lease assets
  7,119,289 
  - 
  Deposits for facilities
  706,852 
  754,533 
  Intangible assets, net
  21,635,000 
  21,635,000 
  Goodwill
  54,669,997 
  54,669,997 
Total other assets
  87,199,047 
  78,775,087 
 
    
    
Total assets
 $111,310,797 
 $94,518,122 
 
See Notes to Condensed Consolidated Financial Statements 
 
 
4
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JUNE 30, 2020 AND SEPTEMBER 30, 2019
(continued)
 
 
 
(Unaudited)
 
 
 
 
 
 
June 30,
 
 
September 30,
 
 
 
2020
 
 
2019
 
Liabilities and shareholders' equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
  Accounts payable
 $1,825,135 
 $3,021,271 
  Accrued expenses
  1,396,983 
  681,269 
  Operating leases – short term liabilities
  1,109,585 
  - 
  Note payable
  54,720 
  - 
  Customer deposit – related party
  - 
  7,339 
Total current liabilities
  4,386,423 
  3,709,878 
 
    
    
Long term liabilities:
    
    
  Long term liabilities
  - 
  363,960 
  Note payable
  182,714 
  - 
  Paycheck Protection Progam loan
  1,456,100 
  - 
  Operating leases - long term liabilities
  6,305,422 
  - 
  Contingent liability
  15,400,000 
  50,600,000 
  Deferred tax liability
  - 
  2,240,300 
Total long term liabilities
  23,344,236 
  53,204,260 
 
    
    
Total liabilities
  27,730,659 
  56,914,138 
 
    
    
cbdMD, Inc. shareholders' equity:
    
    
Preferred stock, authorized 50,000,000 shares, $0.001 par value, 500,000 and 0 shares issued and outstanding, respectively
  500 
  - 
Common stock, authorized 150,000,000 shares, $0.001 par value,
    
    
  51,345,648 and 27,720,356 shares issued and outstanding, respectively
  51,346 
  27,720 
Additional paid in capital
  124,558,046 
  97,186,524 
Accumulated deficit
  (41,029,754)
  (59,610,260)
Total cbdMD, Inc. shareholders' equity
  83,580,138 
  37,603,984 
 
    
    
 
    
    
Total liabilities and shareholders' equity
 $111,310,797 
 $94,518,122 
 
    
    
 
 
See Notes to Condensed Consolidated Financial Statements
 
5
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2020 AND 2019
(Unaudited)
 
 
 
Three months
 
 
Three months
 
 
Nine months
 
 
Nine months
 
 
 
Ended
 
 
Ended
 
 
Ended
 
 
Ended
 
 
 
June 30,
2020
 
 
June 30,
2019
 
 
June 30,
2020
 
 
June 30,
2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Gross Sales
  10,809,387 
  9,734,459 
  30,925,678 
  18,170,667 
 Allowances
  (172,842)
  (1,729,310)
  (741,861)
  (4,063,252)
Total Net Sales
  10,636,545 
  8,005,149 
  30,183,817 
  14,107,414 
   Cost of sales
  3,748,024 
  2,929,160 
  10,180,637 
  5,009,187 
 
    
    
    
    
   Gross Profit
  6,888,521 
  5,075,989 
  20,003,180 
  9,098,228 
 
    
    
    
    
     Operating expenses
  8,226,029 
  11,542,628 
  33,053,962 
  18,683,905 
  Income (Loss) from operations
  (1,337,508)
  (6,466,639)
  (13,050,782)
  (9,585,677)
    Realized and Unrealized gain (loss) on
       marketable securities
  (30,849)
  (13,162)
  (146,011)
  (77,802)
     (Increase) Decrease of contingent
       liability
  (7,580,000)
  (21,547,606)
  30,580,000 
  (52,461,680)
     Impairment on investment other securities
  - 
  - 
  (600,000)
  - 
     Impairment accounts receivable other
    
  - 
  (160,000)
  - 
 
    
    
    
    
   Interest income (expense)
  3,436 
  6,229 
  46,311 
  50,189 
  Income (loss) before provision for
      income taxes
  (8,944,921)
  (28,021,178)
  16,669,518 
  (62,074,970)
 
    
    
    
    
  Benefit (Provision) for income taxes
  - 
  1,088,000 
  2,240,300 
  2,296,000 
  Net Income (Loss) from continuing operations
 
  (8,944,921)
  (26,933,178)
  18,909,818 
  (59,778,970)
  Net Income (Loss) from discontinued operations, net of tax (Note 16)
 
  (7,781)
  (2,269,778)
  (48,983)
  (3,463,123)
   Net Income (Loss)
  (8,952,702)
  (29,202,956)
  18,860,835 
  (63,242,093)
  Net Gain (Loss) attributable to
    noncontrolling interest
  - 
  (1,503,707)
  - 
  (1,641,391)
Preferred dividends
  100,050 
  - 
  266,800 
  - 
 
    
    
    
    
Net Income (Loss) attributable to cbdMD, Inc. common shareholders
 $(9,052,752)
 $(27,699,249)
 $18,594,035 
 $(61,600,702)
 
    
    
    
    
Net Income (Loss) per share:
    
    
    
    
  Basic earnings per share
 $(0.18)
 $(1.19)
 $0.45 
 $(4.22)
  Diluted earnings per share
 $- 
 $- 
 $0.44 
 $- 
 
    
    
    
    
 Weighted average number of shares Basic:
  51,335,648 
  23,193,793 
  41,411,261 
  14,585,619 
 Weighted average number of shares Diluted:
    
    
  42,534,519 
    
 
 
See Notes to Condensed Consolidated Financial Statements
 
6
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2020 AND 2019
(Unaudited)
 
 
 
Three months
 
 
Three months
 
 
Nine months
 
 
Nine months
 
 
 
Ended
 
 
Ended
 
 
Ended
 
 
Ended
 
 
 
June 30,
2020
 
 
June 30,
2019
 
 
June 30,
2020
 
 
June 30,
2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Income (Loss)
 $(8,952,702)
 $(29,202,956)
 $18,860,835 
 $(63,242,093)
  Comprehensive Income (Loss)
  (8,952,702)
  (29,202,956)
  18,860,835 
  (63,242,093)
 
    
    
    
    
Comprehensive Income (loss) attributable to non-controlling interest
  - 
  (1,503,707)
  - 
  (1,641,391)
Preferred dividends
  (100,050)
  - 
  (266,800)
  - 
Comprehensive Income (Loss) attributable to cbdMD, Inc. common shareholders
 $(9,052,752)
 $(27,699,249)
 $18,594,035 
 $(61,600,702)
 
See Notes to Condensed Consolidated Financial Statements
 
7
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED JUNE 30, 2020 AND 2019
(unaudited)
 
 
 
Nine Months Ended June 30,
 
 
Nine Months Ended June 30,
 
 
 
2020
 
 
2019
 
Cash flows from operating activities:
 
 
 
 
 
 
Net Income (loss)
 $18,860,835 
 $(63,242,093)
Adjustments to reconcile net (income) loss to net
    
    
  cash used by operating activities:
    
    
  Stock based compensation
  1,391,271 
  2,022,812 
  Restricted stock expense
  138,001 
  92,000 
  Issuance of stock / warrants for service
  84,450 
  289,750 
  Intangible impairment
  - 
  2,114,334 
  Inventory and materials impairment
  233,372 
  - 
  Impairment on discontinued operations asset
  45,783 
  - 
  Depreciation and amortization
  499,394 
  272,121 
  Gain on settlement of Note
  - 
  (20,000)
  Other than temporary impairment other securities and
    other accounts receivable
  760,000 
  - 
  Increase/(Decrease) in contingent liability
  (30,580,000)
  52,461,680 
  Realized and unrealized loss of marketable securities
  146,011 
  1,705,069 
  Merchant reserve settlement
  132,657 
  - 
  Non-cash consideration received for services
  - 
  (470,000)
  Non-cash lease expense
  878,986 
  - 
Changes in operating assets and liabilities:
    
    
  Accounts receivable
  710,629 
  399,074 
  Accounts receivable – related party
  - 
  204,902 
  Other accounts receivable
  - 
  (298,754)
  Note receivable
  - 
  (27,000)
  Note receivable – related party
  - 
  156,147 
  Deposits
  (147,166)
  - 
  Merchant reserve
  386,912 
  (199,907)
  Inventory
  (2,329,112)
  (2,581,958)
  Prepaid inventory
  621,573 
  - 
  Prepaid expenses and other current assets
  1,007,374 
  (717,894)
  Marketable securities
  - 
  701,593 
  Accounts payable and accrued expenses
  (480,424)
  1,073,211 
  Accounts payable and accrued expenses – related party
  - 
  (313,591)
  Operating lease liability
  (766,289)
  - 
  Note payable
  42,968 
  - 
  Deferred revenue / customer deposits
  (7,339)
  (380,804)
  Collection on discontinued operations accounts receivable
  333,333 
  - 
  Deferred tax liability
  (2,240,300)
  (2,296,000)
Cash used by operating activities
  (10,277,081)
  (9,055,308)
 
    
    
Cash flows from investing activities:
    
    
   Net cash used for merger
  - 
  (1,167,295)
   Purchase of intangible assets
  - 
  (79,999)
   Purchase of property and equipment
  (1,851,746)
  (359,421)
Cash used by investing activities
  (1,851,746)
  (1,606,715)
 
    
    
Cash flows from financing activities:
    
    
   Proceeds from issuance of common stock
  16,771,756 
  19,009,897 
   Proceeds from issuance of preferred stock
  4,421,928 
  - 
   PPP loan
  1,456,100 
  - 
   Note Payable – related party
  - 
  (764,300)
   Preferred dividend distribution
  (266,800)
  - 
   Deferred issuance costs
  62,197 
  (232,914)
Cash provided by financing activities
  22,445,180 
  18,012,683 
Net increase (decrease) in cash
  10,316,353 
  7,350,660 
Cash and cash equivalents, beginning of period
  4,689,966 
  4,282,553 
Cash and cash equivalents, end of period
 $15,006,319 
 $11,633,213 
 
See Notes to Condensed Consolidated Financial Statements
 
8
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED JUNE 30, 2020 AND 2019
(unaudited) (continued)
 
Supplemental Disclosures of Cash Flow Information:
 
 
 
Nine Months ended June 30,
 
 
Nine Months Ended June 30,
 
 
 
2020
 
 
2019
 
 
 
 
 
 
 
 
Cash Payments for:
 
 
 
 
 
 
    Interest expense
 $26,126 
 $36,418 
 
    
    
Non-cash financial activities:
 
    
    
Warrants issued to secondary selling agent
 $524,113 
 $309,592 
Stock received for prior period services, adjusted for other accounts receivable write down prior to receipt
 $- 
 $1,352,000 
Adoption of ASU 2016-01
 $- 
 $2,512,539 
 
    
    
 
See Notes to Condensed Consolidated Financial Statements
 
9
 
 
cbdMD, INC.
CONSOLIDATED STATEMENT OF SHAREHOLDERS' (DEFICIT) EQUITY
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional
 
 
Other
 
 
 
 
 
 
 
 
 
Common stock
 
 
Preferred stock
 
 
Paid in
 
 
Comprehensive
 
 
Accumulated
 
 
 
 
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Income(loss)
 
 
Deficit
 
 
Total
 
Balance, September 30, 2019
  27,720,356 
  27,720 
  - 
  - 
  97,186,524 
  - 
  (59,610,260)
  37,603,984 
Issuance of Preferred stock
  - 
  - 
  500,000 
  500 
  4,421,428 
  - 
  - 
  4,421,928 
Issuance of options for share based compensation
  - 
  - 
    
    
  542,574 
  - 
  - 
  542,574 
Issuance of stock costs
  - 
  - 
    
    
  (31,757)
  - 
  - 
  (31,757)
Issuance of restricted stock for share based compensation
  - 
  - 
  - 
  - 
  138,000 
  - 
  - 
  138,000 
Preferred dividend
  - 
  - 
  - 
  - 
  - 
  - 
  (66,734)
  (66,734)
Adoption of ASU 2016-02
  - 
  - 
  - 
  - 
  - 
  - 
  (13,528)
  (13,528)
Net Income (loss)
  - 
  - 
    
    
  - 
  - 
  12,929,763 
  12,929,763 
Balance, December 31, 2019
  27,720,356 
  27,720 
  500,000 
  500 
  102,256,769 
  - 
  (46,760,759)
  55,524,230 
Issuance of common stock
  23,590,292 
  23,591 
  - 
  - 
  21,368,166 
  - 
  - 
  21,391,757 
Issuance of options for share based compensation
  - 
  - 
  - 
  - 
  429,651 
  - 
  - 
  429,651 
Issuance of stock/warrants for services
  25,000 
  25 
  - 
  - 
  28,225 
  - 
  - 
  28,250 
Preferred dividend
  - 
  - 
  - 
  - 
  - 
  - 
  (100,016)
  (100,016)
Net Income (loss)
  - 
  - 
  - 
  - 
  - 
  - 
  14,883,772 
  14,883,772 
Balance, March 31, 2020
  51,335,648 
  51,336 
  500,000 
  500 
  124,082,811 
  - 
  (31,977,003)
  92,157,644 
Issuance of options for share based compensation
  - 
  - 
  - 
  - 
  419,045 
  - 
  - 
  419,045 
Issuance of stock/warrants for services
  10,000 
  10 
  - 
  - 
  56,190 
  - 
  - 
  56,200 
Preferred dividend
  - 
  - 
  - 
  - 
  - 
  - 
  (100,050)
  (100,050)
Net Income (loss)
  - 
  - 
  - 
  - 
  - 
  - 
  (8,952,702)
  (8,952,702)
Balance, June 30, 2020
  51,345,648 
  51,346 
  500,000 
  500 
  124,558,046 
  - 
  (41,029,755)
  83,580,137 
 
See Notes to Condensed Consolidated Financial Statements
 
10
 
 
cbdMD, INC.
CONSOLIDATED STATEMENT OF SHAREHOLDERS' (DEFICIT) EQUITY
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2019
 
 
 
Common Stock
 
 
Additional Paid in
 
 
Other Comprehensive
 
 
Accumulated
 
 
Non-controlling
 
 
 
 
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Income(loss)
 
 
Deficit
 
 
Interest
 
 
Total
 
Balance, September 30, 2018
  8,123,928 
  8,124 
  21,781,095 
  (2,512,539)
  (6,669,495)
  1,411,972 
  14,019,155 
Issuance of common stock
  1,971,428 
  1,971 
  6,355,027 
  - 
  - 
  - 
  6,356,998 
Issuance of options for share based compensation
  - 
  - 
  143,673 
  - 
  - 
  - 
  143,673 
Issuance of stock costs
  - 
  - 
  (205,569)
  - 
  - 
  - 
  (205,569)
Adoption of ASU 2016-01
  - 
  - 
  - 
  2,512,539 
  (2,512,539)
  - 
  - 
Net loss
  - 
  - 
  - 
  - 
  (2,109,715)
  (79,149)
  (2,188,864)
Balance, December 31, 2018
  10,095,356 
  10,095 
  28,074,224 
  - 
  (11,291,749)
  1,332,823 
  18,125,391 
Issuance of options for share based compensation
  - 
  - 
  19,475 
  - 
  - 
  - 
  19,475 
Issuance of stock and warrants for services
  75,000 
  75 
  289,675 
  - 
  - 
  - 
  289,750 
Net loss
  - 
  - 
  - 
  - 
  (31,791,738)
  (58,536)
  (31,850,274)
Balance, March 31, 2019
  10,170,356 
  10,170 
  28,383,374 
  - 
  (43,083,487)
  1,274,287 
  (13,415,658)
Issuance of common stock for merger
  15,250,000 
  15,250 
  53,199,913 
  - 
  - 
  - 
  53,215,163 
Issuance of common stock
  2,300,000 
  2,300 
  12,650,600 
  - 
  - 
  - 
  12,652,900 
Issuance of options for share based compensation
  - 
  - 
  1,859,664 
  - 
  - 
  - 
  1,859,664 
Issuance of stock costs
  - 
  - 
  (55,393)
  - 
  - 
  - 
  (55,393)
Issuance of stock and warrants for services
    
    
  92,000 
  - 
  - 
  - 
  92,000 
Net loss
  - 
  - 
  - 
  - 
  (27,699,249)
  (1,503,707)
  (29,202,956)
Balance, June 30, 2019
  27,720,356 
  27,720 
  96,130,158 
  - 
  (70,782,736)
  (229,420)
  25,145,722 
 
See Notes to Condensed Consolidated Financial Statements
 
11
 
 
cbdMD, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED JUNE 30, 2020 AND 2019
 
 
NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Organization and Nature of Business
 
cbdMD, Inc. ("cbdMD", "we", "us", “our”, "Parent Company” or the “Company”) is a North Carolina corporation formed on March 17, 2015 as Level Beauty Group, Inc. In November 2016 we changed the name of the Company to Level Brands, Inc. and on May 1, 2019 we changed the name of our Company to “cbdMD, Inc.”. We operate from our offices located in Charlotte, North Carolina. Our fiscal year end is established as September 30.
 
On December 20, 2018 the Company, and its newly organized wholly-owned subsidiaries AcqCo, LLC and cbdMD LLC, completed a two-step merger (the “Mergers”) with Cure Based Development, LLC, a Nevada limited liability company (“Cure Based Development”). Upon completion of the Mergers, cbdMD LLC survived and operates the prior business of Cure Based Development. On April 10, 2019, cbdMD LLC was renamed to CBD Industries LLC (“CBDI”). As consideration for the Mergers, the Company had a contractual obligation, after approval by our shareholders, to issue 15,250,000 shares of our common stock to the members of Cure Based Development, of which 8,750,000 of the shares will vest over a five year period and are subject to a voting proxy agreement, as well as to issue another 15,250,000 shares of our common stock in the future upon earnout goals being within the next 5 years. The Company’s shareholders approved the issuance of the 15,250,000 shares of common stock and they were issued to members of Cure Based Development on April 19, 2019. In addition the first marking period for the earnout was December 31, 2019 and based on measurement criteria, 5,127,792 shares had been earned and were issued on February 27, 2020. CBDI produces and distributes various high-grade, premium cannabidiol oil (“CBD”) products under the cbdMD brand. CBD is a natural substance produced from the hemp plant and the products manufactured by CBDI are non psychoactive as they do not contain tetrahydrocannabinol (THC).
 
On October 22, 2019, cbdMD, Inc. filed Articles of Incorporation with the Secretary of State of North Carolina to form a new wholly-owned subsidiary, Paw CBD, Inc. (“Paw CBD”), in conjunction with the organization of its animal health division. In the third quarter of fiscal 2019 cbdMD, Inc. launched its new CBD pet brand, Paw CBD. Following the initial positive response to the brand from retailers and consumers, cbdMD, Inc. organized Paw CBD, Inc. as a separate wholly-owned subsidiary in an effort to take advantage of its early mover status in the CBD animal health industry.
 
Effective September 30, 2019, the Company abandoned and ceased operations of four business subsidiaries: Encore Endeavor 1, LLC (“EE1”), I’M1, LLC (“IM1”), Beauty and Pin Ups, LLC (“BPU”) and Level H&W, LLC (“Level H&W”). Therefore, the results of operations related to these subsidiaries for the Company are reported as discontinued operations.
 
The accompanying unaudited interim condensed consolidated financial statements of cbdMD have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report filed with the SEC on Form 10-K for the year ended September 30, 2019, as amended (“2019 10-K”). In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of consolidated financial position and the consolidated results of operations for the interim periods presented have been reflected herein. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited consolidated financial statements for fiscal year 2019 as reported in the 2019 10-K have been omitted.
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CBDI and Paw CBD. All material intercompany transactions and balances have been eliminated in consolidation.
 
Use of Estimates
 
The preparation of the Company's consolidated financial statements have been prepared in accordance with US GAAP, and requires management to make estimates and assumptions that affect amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying consolidated financial statements include, but are not limited to, allowances for doubtful accounts, inventory valuation reserves, expected sales returns and allowances, certain assumptions related to the valuation of investments other securities, acquired intangible and long-lived assets and the recoverability of intangible and long-lived assets and income taxes, including deferred tax valuation allowances and reserves for estimated tax liabilities, contingent liability and, hence consideration for the Mergers is a material estimate. Actual results could differ from these estimates.
 
The Company is continuing to monitor data related to impact of the COVID-19 pandemic and at this time, based upon the available data, does not believe there would be an impact on inputs used for estimates and assumptions.
 
 
12
 
 
Cash and Cash Equivalents
 
For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three months when purchased to be cash equivalents.
 
Accounts receivable and Accounts receivable other
 
Accounts receivable are stated at cost less an allowance for doubtful accounts, if applicable. Credit is extended to customers after an evaluation of the customer’s financial condition, and generally collateral is not required as a condition of credit extension. Management’s determination of the allowance for doubtful accounts is based on an evaluation of the receivables, past experience, current economic conditions, and other risks inherent in the receivables portfolio. As of June 30, 2020, we have an allowance for doubtful accounts of $12,288, and had an allowance of ($7,286) at September 30, 2019.
 
In addition, the Company has and may, from time to time, enter into contracts where a portion of the consideration provided by the customer in exchange for the Company's services is common stock, options or warrants (an equity position).  In these situations, upon invoicing the customer for the stock or other instruments, the Company will record the receivable as accounts receivable other, and use the value of the stock or other instrument upon invoicing to determine the value. Where an accounts receivable is settled with the receipt of the common stock or other instrument, the common stock or other instrument will be classified as an asset on the balance sheet as either a marketable security (when the customer is a publicly traded entity) or as an investment other security (when the customer is a private entity). 
 
Receivable and Merchant Reserve
 
The Company primarily sells its products through the internet and has an arrangement to process customer payments with third-party payment processors, and will negotiate the fee based on the market. The arrangement with the payment processors requires that the Company pay a fee between 4.0% - 5.2% of the transaction amounts processed. Pursuant to this agreement, there can be a waiting period between 2 - 5 days prior to reimbursement to the Company, and as well as a calculated reserve which some payment processors hold back. Fees and reserves can change periodically with notice from the processors. At June 30, 2020, the receivable from payment processors included approximately $258,303 for the waiting period amount and is recorded as accounts receivable in the accompanying consolidated balance sheet.
 
Inventory
 
Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and labor (portions of which we outsource to third party manufacturers). Write-offs of potentially slow moving or damaged inventory are recorded based on management’s analysis of inventory levels, forecasted future sales volume and pricing and through specific identification of obsolete or damaged products. We assess inventory quarterly for slow moving products and potential impairments and at a minimum perform a physical inventory count annually near fiscal year end.
 
Customer Deposits
 
Customer deposits consist of payments received in advance of revenue recognition. Revenue is recognized as revenue recognition criteria are met.
 
Property and Equipment
 
Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense over the estimated useful lives of the assets using the straight-line method. Generally, the useful lives are five years for manufacturing equipment and automobiles, three years for computer, furniture and equipment, three years for software, and leasehold improvements are over the term of the lease. The cost and accumulated depreciation of property are eliminated from the accounts upon disposal, and any resulting gain or loss is included in the consolidated statements of operations for the applicable period. Long-lived assets held and used by the Company are reviewed for impairment whenever changes in circumstance indicate the carrying value of an asset may not be recoverable.
 
 
13
 
 
Fair value accounting 
 
The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, fair value accounting standards establish a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).
 
Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are directly or indirectly observable for the asset or liability. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability. Level 3 inputs are unobservable inputs for the asset or liability, which are based on an entity’s own assumptions, as there is little, if any, observable market activity. In instances where the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
 
When the Company records an investment in marketable securities the carrying value is assigned at fair value.  Any changes in fair value for marketable securities during a given period will be recorded as an unrealized gain or loss in the consolidated statement of operations. For investment other securities without a readily determinable fair value, the Company may elect to estimate its fair value at cost less impairment plus or minus changes resulting from observable price changes.
 
Goodwill
 
Goodwill represents the excess of cost of an acquired business over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. Identifiable intangible assets acquired in business combinations are recorded based on their fair values at the date of acquisition. Goodwill is not subject to amortization but must be evaluated for impairment annually. The Company tests for goodwill impairment annually or whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.
 
In performing a goodwill test, the Company performs a qualitative evaluation and if necessary, a quantitative evaluation. Factors considered in the qualitative test include specific operating results as well as new events and circumstances impacting the operations or cash flows of the business acquired. For the quantitative test, the Company assesses goodwill for impairment by comparing the carrying value of the business to the respective fair value. The Company determines the fair value of its acquired business using a combination of income-based and market-based approaches and incorporates assumptions it believes market participants would utilize. The income-based approach utilizes discounted cash flows while the market-based approach utilizes market multiples. These approaches are dependent upon internally-developed forecasts that are based upon annual budgets and longer-range strategic plans. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective acquired business and in the internally-developed forecasts. The Company has analyzed a variety of factors in light of the known impact to date of the COVID-19 pandemic on its business to determine if a circumstance could trigger an impairment loss, and, at this time and based on the information presently known, does not believe it is more likely that an impairment loss has been incurred.
 
Intangible Assets
 
The Company's intangible assets consist of trademarks and other intellectual property, all of which are accounted for in accordance with ASC Topic 350, Intangibles – Goodwill and Other. The Company employs the non-amortization approach to account for purchased intangible assets having indefinite lives. Under the non-amortization approach, intangible assets having indefinite lives are not amortized into the results of operations, but instead are reviewed annually or more frequently if events or changes in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform an impairment analysis at August 1 annually on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18. Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine if the fair value is less than the carrying value of the intangible assets. If a quantitative analysis is necessary, we would analyze various aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. The Company has analyzed a variety of factors in light of the known impact to date of the COVID-19 pandemic on its business to determine if a circumstance could trigger an impairment loss, and, at this time and based on the information presently known, does not believe it is more likely that an impairment loss has been incurred.
 
 
14
 
 
Intangible assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with ASC 360-10-35-21, definite lived intangibles are reviewed annually or more frequently if events or changes in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value.
 
In conjunction with any acquisitions, the Company refers to ASC-805 as amended by Accounting Standards Update (“ASU”) 2017-01 in determining if the Company is acquiring any inputs, processes or outputs and the impact that such factors would have on the classification of the acquisition as a business combination or asset purchase. Additionally, the Company refers to the aforementioned guidance in reviewing all acquired assets and assumed liabilities for valuation in a business combination, including the determination of intangible asset values and contingent liabilities.
 
Contingent liability
 
A significant component of the purchase price consideration for the Company’s acquisition of Cure Based Development includes a fixed number of future shares to be issued as well as a variable number of future shares to be issued based upon the post-acquisition entity reaching certain specified future revenue targets, as further described in Note 8. The Company made a determination of the fair value of the contingent liabilities as part of the valuation of the assets acquired and liabilities assumed in the business combination.
 
The Company recognized both the fixed number of shares to be issued, and the variable number of shares to be potentially issued, as contingent liabilities on its Consolidated Balance Sheets. These contingent liabilities were recorded at fair value upon the acquisition date and are remeasured quarterly based on the reassessed fair value as of the end of that quarterly reporting period. Additionally, as the fixed shares were issued on April 19, 2019, the value of the shares at that time, in the amount of $53,215,163, was reclassified from contingent liability to additional paid in capital on the balance sheet. In addition the first marking period for the Earnout Shares was December 31, 2019 and based on measurement criteria, 5,127,792 shares were issued on February 27, 2020. The value of the issued Earnout Shares as of February 27, 2020 was $4,620,000 and the decrease in value of $6,924,503 from December 31, 2019 related to those shares was recorded in the Statement of Operations for the three months ended March 31, 2020. Additionally, as the 5,127,792 Earnout Shares were issued on February 27, 2020, the value of the shares in the amount of $4,620,000 was reclassified from the contingent liability to additional paid in capital on the balance sheet.
 
For the three months ended June 30, 2020, the contingent liabilities associated with the business combination were increased by $7,580,000 to reflect their reassessed fair values as of June 30, 2020. This increase is reflective of a change in value of the variable number of shares from March 31, 2020. In May 2020, the Company updated the forecasts for performance of the post-acquisition entity based on current trends and performance that would impact the estimated likelihood that the revenue targets disclosed in Note 8 would be met. The primary catalyst for the $7,580,000 increase in contingent liabilities is the change in the Company’s common share price between June 30, 2020 and March 31, 2020. These increases or decreases to the contingent liabilities are reflected within Other Income (Expenses) on the consolidated statements of operations.
 
Paycheck Protection Program Loan
 
On April 27, 2020, we received a loan in the principal amount of $1,456,100 (the “SBA Loan”), under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, we are using the proceeds from this loan to primarily help maintain our payroll as we navigate our business with a focus on returning to normal operations. The term of the Note is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. We intend to use the SBA Loan for qualifying expenses and to apply for forgiveness of the SBA Loan in accordance with the terms of the CARES Act.
 
In June 2020, the Payroll Protection Program Flexibility Act (“PPPFA”) was signed into law adjusting certain key terms of loans issued under the PPP. In accordance with the PPPFA, the initial deferral period may be extended from six to up to ten months and the loan maturity may be extended from two to five years. The PPPFA also provided for certain other changes, including the extent to which the loan may be forgiven.
 
As the legal form of the Promissory Note is a debt obligation, the Company is accounting for it as debt under Accounting Standards Codification (ASC) 470, Debt and recorded an initial liability of $1,456,100 in the condensed consolidated balance sheet upon receipt of the loan proceeds. The Company is accruing interest over the term of the loan and is not imputing additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest excludes transactions where interest rates are prescribed by a government agency. If any amount of the loan is ultimately forgiven, income from the extinguishment of debt would be recognized as a gain on loan extinguishment in the consolidated statement of operations and comprehensive income.
 
 
15
 
 
Revenue Recognition
 
The Company adopted ASC 606, Revenue from Contracts with Customers using the modified retrospective method beginning with our quarter ended December 31, 2018. The adoption of the new revenue standards as of October 1, 2018 did not change the Company’s revenue recognition as the majority of its revenues continue to be recognized when the customer takes control of its product or the services have been rendered. As the Company did not identify any accounting changes that impacted the amount of reported revenues with respect to any of its revenue streams, no adjustment to retained earnings was required upon adoption.
 
Under ASC 606, the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.
 
Performance Obligations
 
A performance obligation is a promise in a contract to transfer a distinct good or service to a customer. For our CBD products, the Company meets that obligation when it has shipped products which have been ordered to the customer. The Company has reviewed its various revenue streams for its other contracts under the five-step approach.
 
At June 30, 2020, the Company has no future performance obligations.
 
Allocation of transaction price
 
In our current business model we do not have contracts with customers which have multiple elements as revenue is driven purely by online product sales or purchase order based product sales. However, at times in the past, the Company had entered into contracts with customers wherein there were multiple elements that may have disparate revenue recognition patterns. In such instances, the Company must allocate the total transaction price to these various elements. This is achieved by estimating the standalone selling price of each element, which is the price at which we sell a promised good or service separately to a customer.
 
In circumstances where we have not historically sold relevant products or services on a standalone basis, the Company utilizes the most situationally appropriate method of estimating standalone selling price. These methods include (i) an adjusted market assessment approach, wherein we refer to prices from our competitors for similar goods or serves and adjust those prices as necessary to reflect our typical costs and margins, (ii) an expected cost plus margin approach, wherein we forecast the costs that we will incur in satisfying the identified performance obligation and adding an appropriate margin to such costs, and (iii) a residual approach, wherein we adjust the total transaction price to remove all observable standalone selling prices of other goods or services included in the contract and allocate the entirety of the remaining contract amount to the remaining obligation.
 
Revenue recognition
 
The Company records revenue from the sale of its products when risk of loss and title to the product are transferred to the customer, which is upon shipping (and is typically FOB shipping) which is when our performance obligation is met. Net sales are comprised of gross revenues less product returns, trade discounts and customer allowances, which include costs associated with off-invoice mark-downs and other price reductions, as well as trade promotions. These incentive costs are recognized at the later of the date on which the Company recognizes the related revenue or the date on which the Company offers the incentive. The Company currently offers a 60 day, money back guarantee.
 
In regard to sales for services provided, the Company records revenue when the customer has accepted services and the Company has a right to payment. Based on the contracted services, revenue is recognized when the Company invoices customers for completed services at agreed upon rates or revenue is recognized over a fixed period of time during which the service is performed. 
 
Disaggregated Revenue
 
Our product revenue is generated primarily through two sales channels, consumer (E-commerce) and wholesale channels. We also have generated service related sales, although this type of revenue is not a primary focus. We believe that these categories appropriately reflect how the nature, amount, timing and uncertainty of revenue and cash flows are impacted by economic factors.
 
 
16
 
 
A description of our principal revenue generating activities are as follows:
 
- Consumer (E-commerce) sales - consumer products sold through our online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due prior to the date of shipment.
 
- Wholesale sales - products sold to our wholesale customers for subsequent resale. Revenue is recognized when control of the goods is transferred to the customer, in accordance with the terms of the applicable agreement. Payment terms vary and can typically be 30 days from the date control over the product is transferred to the customer.
 
- Service related sales – services provided to organizations typically consulting services related to branding, marketing, or advisory. Revenue is recognized when services are delivered to the customer, in accordance with the terms of the applicable agreement. Payment terms vary and typically are based on deliverables and agreed upon timelines.
 
The following table represents a disaggregation of revenue by sales channel:
 
 
 
Three Months ended
June 30, 2020
 
 
 
% of total
 
 
Three Months ended
June 30, 2019
 
 
 
 
% of total
 
Wholesale product sales
 $2,410,719 
  22.7%
 $3,366,807 
  42.1%
Consumer product sales
  8,225,826 
  77.3%
  4,638,342 
  57.9%
Service related sales
  - 
  0%
  - 
  0%
Total net sales
 $10,636,545 
    
 $8,005,149 
    
 
 
 
Nine Months ended
June 30, 2020
 
 
 
% of total
 
 
Nine Months ended
June 30, 2019
 
 
 
 
% of total
 
Wholesale product sales
 $8,238,832 
  27.3%
 $4,741,900 
  33.6%
Consumer product sales
  21,944,985 
  72.7%
  9,365,514 
  66.4%
Service related sales
  - 
  0%
  - 
  0%
Total net sales
 $30,183,817 
    
 $14,107,414 
    
 
 
Contract Balances
 
Contract assets represent unbilled receivables and are presented within accounts receivable, net on the condensed consolidated balance sheets. Contract liabilities represent unearned revenues and are presented as deferred revenue or customer deposits on the condensed consolidated balance sheets.
 
We have no contract assets and contract liabilities at June 30, 2020.
 
Cost of Sales
 
Our cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, third-party providers, and outbound freight for our products sales, and includes labor for our service sales. For our product sales, cost of sales also includes the cost of refurbishing products returned by customers that will be offered for resale, if any, and the cost of inventory write-downs associated with adjustments of held inventories to their net realizable value. These expenses are reflected in the Company’s consolidated statements of operations when the product is sold and net sales revenues are recognized or, in the case of inventory write-downs, when circumstances indicate that the carrying value of inventories is in excess of their net realizable value.
 
 
17
 
 
Advertising Costs
 
The Company expenses all costs of advertising and related marketing and promotional costs as incurred. The Company incurred approximately $1,699,262 and $2,582,685 in advertising and related marketing and promotional costs included in operating expenses during the three months ended June 30, 2020 and 2019, respectively. The Company incurred approximately $7,534,488 and $4,174,166 in advertising and related marketing and promotional costs included in operating expenses during the nine months ended June 30, 2020 and 2019, respectively.
 
Shipping and Handling Fees and Costs
 
All fees billed to customers for shipping and handling are classified as a component of sales. All costs associated with shipping and handling are classified as a component of cost of goods sold.
 
Income Taxes
 
The Parent Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. Prior to April 2017, BPU was a multi-member limited liability company that was treated as a partnership for federal and state income tax purposes. Prior to December 2018, IM1 and EE1, were also multi-member limited liability companies that were treated as a partnership for federal and state income tax purposes As such, the Parent Company’s partnership share in the taxable income or loss of BPU, IM1 and EE1 was included in the tax return of the Parent Company. Effective September 30, 2019, the Company abandoned and ceased operations of EE1, IM1, BPU and Level H&W. As of October 1, 2019, CBDI and Paw CBD are wholly owned subsidiaries and are disregarded entities for tax purposes and their entire share of taxable income or loss is included in the tax return of the Parent Company.
 
The Parent Company accounts for income taxes pursuant to the provisions of the Accounting for Income Taxes topic of the FASB ASC 740 which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Parent Company uses the inside basis approach to determine deferred tax assets and liabilities associated with its investment in a consolidated pass-through entity. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.
 
US GAAP requires management to evaluate tax positions taken by the Company and recognize a tax liability (or asset) if the Company has taken an uncertain tax position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has analyzed the tax positions taken by the Company, and has concluded that as of June 30, 2020 and 2019, there were no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the consolidated financial statements.
 
Concentrations
 
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.
 
The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers $250,000 for substantially all depository accounts. The Company from time to time may have amounts on deposit in excess of the insured limits. The Company had a $14,589,707 uninsured balance at June 30, 2020 and a $4,097,190 uninsured balance at September 30, 2019.
 
Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not have any customers that represented a significant amount of our sales for the three and nine months ended June 30, 2020. We have three customers whose aggregate accounts receivable balance was approximately 60% of the combined total accounts receivable and accounts receivable discontinued operations as of June 30, 2020, of which one customer is from the discontinued operations and accounts for approximately 47%. The aggregate accounts receivable balance of such customers represented approximately 51% of the Company’s total accounts receivable as of September 30, 2019.
 
Stock-Based Compensation
 
We account for our stock compensation under the ASC 718-10-30, Compensation - Stock Compensation using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments.
 
We use the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. The Company recognizes forfeitures when they occur.
 
 
18
 
 
Earnings (Loss) Per Share
 
The Company uses ASC 260-10, Earnings Per Share for calculating the basic and diluted income (loss) per share. The Company computes basic income (loss) per share by dividing net income (loss) and net income (loss) attributable to common shareholders, after deducting preferred stock dividends, by the weighted average number of common shares outstanding. Common equivalent shares are excluded from the computation of net loss per share if their effect is anti-dilutive.
 
New Accounting Standards
 
On October 1, 2019, the Company adopted ASU No. 2016-02, Leases, and subsequently issued clarifying guidance. Under the new guidance, lessees are required to recognize assets and lease liabilities for the rights and obligations created by leased assets previously classified as operating leases. In July 2018, the FASB issued ASU No. 2018-11, which permitted entities to record the impact of adoption using a modified retrospective method with any cumulative-effect as an adjustment to retained earnings (accumulated deficit) as opposed to restating comparative periods for the effects of applying the new standard. The Company elected this transition approach; therefore, the Company’s prior period reported results are not restated to include the impact of this adoption. We also elected the practical expedient permitted under the transition guidance which permits companies not to reassess prior conclusions on lease identification, historical lease classification and initial direct costs. In connection with the adoption of the new guidance, the Company recognized an operating lease asset for $7,704,109 and operating lease liability of $7,950,803 and a reduction of retained earnings of $13,528 in its balance sheet as of December 31, 2019, with no impact to its results of operations and cash flows. The difference between the leased assets and lease liabilities represents the net position of existing prepaid rent and deferred rent liabilities balance, resulting from historical straight-lining of operating leases, which were effectively reclassified upon adoption to reduce the measurement of the leased assets.
 
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820). The ASU modifies, removes, and adds several disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is evaluating the effect ASU 2018-13 will have on its consolidated financial statements and disclosures and has not yet determined the effect of the standard on its ongoing financial reporting at this time.
 
NOTE 2 – ACQUISITIONS
 
On December 20, 2018 (the “Closing”), the Company, and its newly organized wholly-owned subsidiaries AcqCo, LLC and cbdMD LLC, both North Carolina limited liability companies, completed a two-step merger (the “Merger Agreement”) with Cure Based Development. The Merger Agreement provided that AcqCo LLC merged with and into Cure Based Development with Cure Based Development as the surviving entity (the “Merger”), and immediately thereafter Cure Based Development merged with and into cbdMD LLC with cbdMD LLC as the surviving entity (the “Secondary Merger” and collectively with the Merger, the “Mergers”). cbdMD LLC was renamed on April 10, 2019 to CBDI and has continued as a wholly-owned subsidiary of the Company and maintains the operations of Cure Based Development pre-closing. As consideration for the Merger, the Company had a contractual obligation, after approval by our shareholders, to issue 15,250,000 shares of our common stock to the members of Cure Based Development, of which unrestricted voting rights to 8,750,000 of the shares vest over a five year period and are subject to a voting proxy agreement. The Merger Agreement also provides that an additional 15,250,000 shares of our common stock can be issued upon the satisfaction of aggregate net revenue criteria by CBDI, within 60 months following the Closing. The net revenue criteria are: $20.0, $40.0, $80.0 and $160.0 million, in aggregate $300.0 million (See Note 8 for more information).
 
The initial 15,250,000 shares were approved by our shareholders and issued on April 19, 2019. On February 27, 2020, 5,127,792 shares were issued upon satisfaction of aggregate net revenue criteria per the Merger Agreement.
 
The Company owns 100% of the equity interest of CBDI. The valuation and purchase price allocation for the Mergers was finalized at September 30, 2019.
 
 
19
 
 
The following table presents the final purchase price allocation:
 
Consideration
 $74,353,483 
 
    
Assets acquired:
    
   Cash and cash equivalents
 $1,822,331 
   Accounts receivable
  850,921 
   Inventory
  1,054,926 
   Other current assets
  38,745 
   Property and equipment, net
  723,223 
   Intangible assets
  21,585,000 
   Goodwill
  54,669,997 
Total assets acquired
  80,745,143 
 
    
Liabilities assumed:
    
   Accounts payable
  257,081 
   Notes payable – related party
  764,300 
   Customer deposits - related party
  265,000 
   Accrued expenses
  460,979 
   Deferred tax liability
  4,644,300 
Total Liabilities assumed
  6,391,660 
 
    
Net Assets Acquired
 $74,353,483 
 
The goodwill generated from this transaction can be attributed to the benefits the Company expects to realize from the growth strategies the acquired Company had developed and the entry into an emerging market with high growth potential. See Note 8 regarding contingent liability.
 
In connection with the purchase price allocation, the Company recorded a deferred tax liability of approximately $4,644,000, with a corresponding increase to goodwill, for the tax effect of the acquired intangible assets from Cure Base Development. This liability was recorded as there will be no future tax deductions related to the acquired intangibles, and we have identified these as indefinite-lived intangible assets.
 
The Company also acquired estimated net operating loss carryforwards of approximately $1,996,000. Under Internal Revenue Code (IRC) Section 382, the use of net operating loss (“NOL”) carryforwards may be limited to an annual limit if a change in ownership of a company occurs.
 
NOTE 3 – MARKETABLE SECURITIES AND INVESTMENT OTHER SECURITIES
 
The Company has, from time to time, entered into contracts where a portion of the consideration provided by the customer in exchange for the Company's services was common stock, options or warrants (an equity position).  In these situations, upon invoicing the customer for the stock or other instruments, the Company recorded the receivable as accounts receivable other, and used the value of the stock or other instrument upon invoicing to determine the value. If there was insufficient data to support the valuation of the security directly, the company would value it, and the underlying revenue, on the estimated fair value of the services provided. Where an accounts receivable other was settled with the receipt of the common stock or other instrument, the common stock or other instrument was classified as an asset on the balance sheet as either an investment marketable security (when the customer was a public entity) or as an investment other security (when the customer was a privately held entity). 
 
On December 30, 2017 the Company entered into an Agreement with Isodiol which is a developer of pharmaceutical grade phytochemical compounds and a manufacturer and developer of phytoceutical consumer products. As payment for these services, the Company has received 1,226,435 shares of Isodiol common stock between December 31, 2017 and January 2019. The Company also received 38,095 shares of Isodiol stock upon Isodiol’s acquisition of Kure Corp, giving the Company a total of 1,264,530 shares. At June 30, 2020, the Company has 1,042,193 shares valued at $52,527.
 
 
20
 
 
The table below summarizes the assets valued at fair value as of June 30, 2020:
 
 
 
In Active Markets for Identical Assets and Liabilities
(Level 1)
 
 
Significant Other Observable Inputs
 (Level 2)
 
 
 
Significant Unobservable Inputs
 (Level 3)
 
 
 
 
Total Fair Value at June 30,
2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities
 $52,527 
  - 
 $- 
 $52,527 
Investment other securities
  - 
  - 
 $- 
 $- 
 
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
 
Total
 
Balance at September 30, 2019
 $198,538 
 $- 
 $600,000 
 $798,538 
Change in value of equities
 $(62,011)
 $- 
 $- 
 $(62,011)
Balance at December 31, 2019
 $136,527 
 $- 
 $600,000 
 $736,527 
Change in value of equities
 $(53,152)
 $- 
 $(600,000)
 $(653,152)
Balance at March 31, 2020
 $83,375 
 $- 
 $- 
 $83,375 
Change in value of equities
 $(30,848)
 $- 
 $- 
 $(30,848)
Balance at June 30, 2020
 $52,527 
 $- 
 $- 
 $52,527 
 
NOTE 4 – INVENTORY
 
Inventory at June 30, 2020 and September 30, 2019 consists of the following:
 
 
 
June 30,
2020
 
 
September 30,
2019
 
Finished goods
 $4,019,683 
 $3,050,120 
Inventory components
  2,377,643 
  1,251,466 
Inventory prepaid
  281,885 
  903,458 
Total
 $6,679,211 
 $5,205,044 
 
Abnormal amounts of idle facility expense, freight, handling costs, scrap, and wasted material (spoilage) are expensed in the period they are incurred. During the three months ended June 30, 2020 and 2019, the Company incurred an abnormal charge of $233,372 and $0, respectively due to the scrapping of certain inventory during the period. This charge was recorded in Other Expense.
 
NOTE 5 – PROPERTY AND EQUIPMENT
 
Major classes of property and equipment at June 30, 2020 and September 30, 2019 consist of the following:
 
 
 
June 30,
2020
 
 
September 30,
2019
 
Computers, furniture and equipment
 $317,369 
 $131,077 
Manufacturing equipment
  2,594,675 
  1,375,986 
Leasehold improvements
  822,719 
  375,954 
Automobiles
  24,892 
  24,892 
 
  3,759,655 
  1,907,909 
Less accumulated depreciation
  (691,746)
  (192,352)
Net property and equipment
 $3,067,909 
 $1,715,557 
 
 
21
 
 
Depreciation expense for continuing operations related to property and equipment was $211,937 and $57,874 for the three months ended June 30, 2020 and 2019, respectively and was $499,394 and $111,913 for the nine months ended June 30, 2020 and 2019, respectively. Depreciation expense for discontinued operations related to property and equipment was $0 and $7,654 for the three and nine months ended June 30, 2019, respectively.
 
NOTE 6 – INTANGIBLE ASSETS
 
With the Mergers of Cure Based Development, the Company made a strategic shift toward the CBD business and all entities and their associated intangibles were assessed during the year ended September 30, 2019 with that focus and their ability to support that business line.
 
On December 20, 2018, the Company completed the Mergers with Cure Based Development and acquired certain assets, including the trademark "cbdMD" and its variants and certain other intellectual property. The trademark is the cornerstone of this subsidiary and is key as we create and distribute products and continue to build this brand. We believe the trademark does not have limits on the time it will contribute to the generation of cash flows and therefore we have identified these as indefinite-lived intangible assets (see Note 2 for more information).
 
In September 2019, the Company purchased the rights to the trademark name HempMD for $50,000. This trademark will be used in the marketing and branding of certain products to be released under this brand name. We believe the trademark does not have limits on the time it will contribute to the generation of cash flows and therefore we have identified these as indefinite-lived intangible assets.
 
Intangible assets as of June 30, 2020 and September 30, 2019 consisted of the following:
 
 
 
June 30,
2020
 
 
September 30,
2019
 
Trademark related to cbdMD
 $21,585,000 
 $21,585,000 
Trademark for HempMD
  50,000 
  50,000 
Total
 $21,635,000 
 $21,635,000 
 
NOTE 7 – PRO FORMA FINANCIAL INFORMATION (UNAUDITED)
 
The following unaudited pro-forma data summarizes the results of operations for the three and nine months ended June 30, 2020 and 2019, as if the Mergers with Cure Based Development had been completed on October 1, 2017. The pro-forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the Mergers had taken place on October 1, 2017. The pro-forma financial information represents the continuing operations only.
 
 
 
Three Months Ended
June 30, 2020
 
 
Three Months Ended
June 30, 2019
 
 
 
 
 
 
 
 
Net revenues
 $N/A* 
 $N/A* 
Operating income (loss)
 $N/A* 
 $N/A* 
Net income (loss)
 $N/A* 
 $N/A* 
Net loss per share – basic and fully diluted
 $N/A* 
 $N/A* 
 
 
 
Nine Months Ended
June 30, 2020
 
 
Nine Months Ended
June 30, 2019
 
 
 
 
 
 
 
 
Net revenues
 $N/A* 
 $17,190,842 
Operating income (loss)
 $N/A* 
 $(10,786,729)
Net income (loss)
 $N/A* 
 $(64,501,471)
Net loss per share – basic and fully diluted
 $N/A* 
 $(2.54)
 
* All entities were consolidated effective December 21, 2018 therefore, the results of operations are included in these condensed financial statements.
 
For the per share calculation prior to April 2019, it is being assumed that the shares to be issued contractually under the Merger Agreement, upon shareholder approval, were issued at the beginning of each period. This would account for an additional 6,500,000 shares issued directly to the members of Cure Based Development and another 8,750,000 shares issued which would have a voting proxy and leak out on voting rights over a 5 year period. 
 
 
22
 
  
NOTE 8 – CONTINGENT LIABILITY
 
As consideration for the Mergers, described in Note 2, the Company had a contractual obligation to issue 15,250,000 shares of our common stock, after approval by our shareholders, to the members of Cure Based Development, issued in two tranches 6,500,000 and 8,750,000, both of which are subject to leak out provisions, and the unrestricted voting rights to 8,750,000 tranche of shares will also vest over a five year period and are subject to a voting proxy agreement. The Merger Agreement also provides that an additional 15,250,000 shares of our common stock can be issued upon the satisfaction of certain aggregate net revenue criteria by cbdMD within 60 months following the Closing Date (“Earn Out”).
 
The contractual obligations and earn out provision are accounted for as a contingent liability and fair value is determined using Level 3 inputs, as estimating the fair value of these contingent liabilities require the use of significant and subjective inputs that may and are likely to change over the duration of the liabilities with related changes in internal and external market factors.
 
The initial two tranches totaling 15,250,000 shares have been valued using a market approach method and included the use of the following inputs: share price upon contractual obligation, discount for lack of marketability to address leak out restrictions, and probability of shareholder disapproval. In addition, the 8,750,000 shares in the second tranche also included an input for a discount for lack of voting rights during the vest periods.
 
The Merger Agreement also provides that an additional 15,250,000 shares (“Earnout Shares”) would be issued as part of the consideration for the Mergers, upon the satisfaction of certain aggregate net revenue criteria by cbdMD within 60 months following the Closing Date as follows, as measured at four intervals (each a “Marking Period”): the completion of 12, 24, 42, and 59 calendar months from the Closing Date, and based upon the ratios set forth below:
 
 Aggregate Net Revenues
 
Shares Issued / Each $ of Aggregate Net Revenue Ratio
 
 
 
  $1 - $20,000,000 
 
    .190625 
  $20,000,001 - $60,000,000 
 
    .0953125 
  $60,000,001 - $140,000,000 
 
    .04765625 
  $140,000,001 - $300,000,000 
 
    .023828125 
 
For clarification purposes, the Aggregate Net Revenues during a Marking Period shall be multiplied by the applicable Shares Issued/Each $ of Aggregate Net Revenue Ratio, minus, the number of shares issued as a result of Aggregate Net Revenues during the prior Marking Periods.
 
The initial 15,250,000 shares and the Earnout Shares were approved by our shareholders and the initial shares were issued on April 19, 2019. The initial shares were issued upon shareholder approval on April 19, 2019 and had a carrying value of $53,215,163. Additionally, as the 15,250,000 initial shares were issued, the value of the shares in the amount of $53,215,163 was reclassified from the contingent liability to additional paid in capital on the balance sheet. In addition, the first marking period for the Earnout Shares was December 31, 2019 and based on measurement criteria, 5,127,792 shares were issued on February 27, 2020 and had a value of $4,620,000. Additionally, as the 5,127,792 Earnout Shares were issued on February 27, 2020, the value of the shares in the amount of $4,620,000 was reclassified from the contingent liability to additional paid in capital on the balance sheet.
 
The 15,250,000 Earnout Shares which would be issued in the future, upon the satisfaction of net revenue criteria have been valued using a Monte Carlo Simulation. Inputs used included: stock price, volatility, interest rates, revenue projections, and likelihood of obtaining revenue projections, amongst others.
 
The value of the contingent liability was $15,400,000 and $7,820,000 at June 30, 2020 and March 31, 2020, respectively, and represents the balance of Earnout Shares for potential future issuance. The increase in value of $7,580,000 is recorded in the Statement of Operations for the three months ended June 30, 2020. The Company utilized both a market approach and a Monte Carlo simulation in valuing the contingent liability and a key input in both of those methods is the stock price. The main driver of the change in the value of the Earnout Shares within the contingent liability was the increase of the Company’s stock price, which was $1.91 at June 30, 2020 as compared to $0.93 on March 31, 2020.
 
NOTE 9 – RELATED PARTY TRANSACTIONS
 
On December 20, 2018, with the closing of the Merger Agreement with Cure Based Development, we recognized the following related party transactions which happened prior to the Mergers:
 
Cure Based Development received $90,000 from Verdure Holdings LLC for future orders of the Company’s products. Verdure Holdings LLC, at that time, was an affiliate of the CEO of Cure Based Development. This amount has been adjusted based on sales to Verdure Holdings subsequent to the mergers and is recorded as customer deposits - related party on the accompanying balance sheet and was $0 and 7,339 at June 30, 2020 and September 30, 2019, respectively.
 
Cure Based Development entered a lease for office space, which also provides administrative and IT services, from an affiliate of the CEO of Cure Based Development. The lease was a month to month lease for $9,166 per month and ended September 2019.
 
Cure Based Development leases its manufacturing facility from an entity partially owned by an individual who now has a contractual right to receive shares of the Company as part of the Mergers. The current lease was entered into on December 15, 2018 and ends December 15, 2021 and has been amended at an annual base rent rate of $199,200 allowing for a 3% annual increase. In addition, common area maintenance rent is set at $25,200 annually.
 
 
23
 
 
NOTE 10 – SHAREHOLDERS’ EQUITY
 
Preferred Stock – We are authorized to issue 50,000,000 shares of preferred stock, par value $0.001 per share. In October 2019, the Company designated 5,000,000 of these shares as 8.0% Series A Cumulative Convertible Preferred Stock. Our 8.0% Series A Cumulative Convertible Preferred Stock ranks senior to our common stock for liquidation or dividend provisions and holders are entitled to receive cumulative cash dividends at an annual rate of 8.0% payable monthly in arrears for the prior month. The Company reviewed ASC 480 – Distinguishing Liabilities from Equity in order to determine the appropriate accounting treatment for the preferred stock and determined that the preferred stock should be treated as equity. There were 500,000 shares of 8.0% Series A Cumulative Convertible Preferred Stock issued and outstanding at June 30, 2020.
 
The total amount of dividends declared and paid were $100,050 and $100,050, respectively, for the three months ended June 30, 2020. The total amount of dividends declared and paid were $266,800 and $266,800, respectively, for the nine months ended June 30, 2020.
 
Common Stock – We are authorized to issue 150,000,000 shares of common stock, par value $0.001 per share. There were 51,345,648 and 27,720,356 shares of common stock issued and outstanding at June 30, 2020 and September 30, 2019, respectively.
 
Preferred stock transactions:
 
In the three and nine months ended June 30, 2020:
 
On October 16, 2019, the Company completed a follow-on firm commitment underwritten public offering of 500,000 shares of its 8.0% Series A Cumulative Convertible Preferred Stock for aggregate gross proceeds of $5,000,000. The Company received approximately $4.5 million in gross proceeds after deducting underwriting discounts and commissions. The Company also issued to the selling agent warrants to purchase in aggregate 47,923 shares of common stock with an exercise price of $3.9125. The warrants were valued at $178,513 and expire on October 10, 2024.
 
No preferred stock was issued in the three and nine months ended June 30, 2019.
 
Common stock transactions:
 
In the three and nine months ended June 30, 2020:
 
On January 14, 2020, the Company completed a follow-on firm commitment underwritten public offering of 18,400,000 shares of its common stock for aggregate gross proceeds of $18,400,000. The Company received approximately $16.9 million in net proceeds after deducting underwriting discounts and commissions. The Company also issued to the selling agent warrants to purchase in aggregate 480,000 shares of common stock with an exercise price of $1.25. The warrants were valued at $345,600 and expire on January 14, 2025.
 
In February 2020, we issued 25,000 shares of our common stock to an investor relations firm for services. The shares were valued at $28,250, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending January 2021.
 
In February 2020, we issued 5,000 shares of our common stock to an employee. The shares were valued at $5,650, based on the trading price upon issuance, and was expensed as stock based compensation expense.
 
In the three and nine months ended June 30, 2019:
 
On October 2, 2018, the Company completed a follow-on firm commitment underwritten public offering of 1,971,428 shares of its common stock for aggregate gross proceeds of approximately $6.9 million. The Company received approximately $6.3 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The Company also issued to representatives of the underwriters warrants to purchase in aggregate 51,429 shares of common stock with an exercise price of $4.375. The warrants were valued at $86,092 and expire on September 28, 2023.
 
In January 2019, we issued 25,000 shares of our common stock to an investment banking firm for general financial advisory services. The shares were valued at $77,250, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending December 2019.
 
 
24
 
 
In January 2019, we issued 50,000 shares of our common stock to an investment banking firm for general advisory and investment bank services. The shares were valued at $212,500, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending April 2020.
 
In April 2019, we issued 15,250,000 shares or our common stock as consideration for the Mergers with Cure Based Development, of which 8,750,000 of the shares will vest over a five year period and are subject to a voting proxy agreement.
 
In May 2019, the Company completed a secondary public offering of 2,300,000 shares of its common stock for aggregate gross proceeds of $13.8 million. The Company received approximately $12.5 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The Company also issued to the selling agent warrants to purchase in aggregate 60,000 shares of common stock with an exercise price of $7.50. The warrants were valued at $223,500 and expire on May 15, 2024.
 
Stock option transactions:
 
In the three and nine months ended June 30, 2020:
 
In December 2019 we granted an aggregate of 280,000 common stock options to two executives. The options vest 1/3 on January 1, 2020, 1/3 on January 1, 2021 and 1/3 on January 1, 2022, have an exercise price of $3.15 per share and a term of five years. We have recorded an expense for the options of $71,540 and $333,856 for the three and nine months ended June 30, 2020, respectively.
 
In February 2020, we granted an aggregate of 30,000 common stock options to an employee. The options vest 1/3 at grant, 1/3 on February 7, 2021, and 1/3 on February 7, 2022, have an exercise price of $3.15 per share and a term of five years. We have recorded an expense for the options of $1,894 and $8,206 for the three and nine months ended June 30, 2020, respectively.
 
In May 2020 we granted per the annual board compensation plan, an aggregate of 80,000 common stock options to four independent directors and are expensed over the annual board term. The options vest immediately, have an exercise price of $1.57 per share and a term of ten years. We have recorded an expense for the options of $29,020 for the three and nine months ended June 30, 2020.
 
In the three and nine months ended June 30, 2019:
 
In May 2019 we granted per the annual board compensation plan, an aggregate of 120,000 common stock options to six independent directors. The options vest immediately, have an exercise price of $5.41 per share and a term of ten years. We have recorded an expense for the options of $562,440 for the three and nine months ending June 30, 2019.
 
In May 2019 we granted an aggregate of 610,000 common stock options to twelve employees. The options vary in amounts issued and vesting tiers, which include no vesting with an exercise price of $6.40, vesting at May 15, 2020 with an exercise price of $7.00, vesting at May 15, 2021 with an exercise price of $7.50, and vesting at May 15, 2022 with an exercise price of $7.50. The options have a term of ten years. We have recorded an expense for the options of $1,290,732 for the three and nine months ended June 30, 2019.
 
The expected volatility rate was estimated based on comparison to the volatility of a peer group of companies in similar industries. The expected term used was the full term of the contract for the issuances. The risk-free interest rate for periods within the contractual life of the option is based on U.S. Treasury securities. The pre-vesting forfeiture rate of zero is based upon the experience of the Company. As required under ASC 718, we will adjust the estimated forfeiture rate to our actual experience. Management will continue to assess the assumptions and methodologies used to calculate estimated fair value of share-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies, and thereby materially impact our fair value determination.
 
The following table summarizes the inputs used for the Black-Scholes pricing model on the options issued in the nine months ended June 30, 2020 and 2019:
 
 
 
 2020
 
 
   2019
 
Exercise price
 $1.57-$3.15  
 $5.41-$7.50 
Risk free interest rate
  0.69%-1.64
  2.41%-2.47%
Volatility
  95.96%-111.31%
  89.60%-90.68%
Expected term
  5-10 years  
  10 years  
Dividend yield
  None 
  None 
 
 
25
 
 
Warrant transactions:
 
In the three and nine months ended June 30, 2020:
 
In October 2019 in relation to the follow-on firm commitment underwritten public offering of the 8.0% Series A Cumulative Convertible Preferred Stock, we issued to the representative of the underwriters warrants to purchase in aggregate 47,923 shares of common stock with an exercise price of $3.9125. The warrants expire on October 10, 2024.
 
In January 2020 in relation to the follow-on firm commitment underwritten public offering of the Company’s common stock, we issued to the representative of the underwriters warrants to purchase in aggregate 480,000 shares of common stock with an exercise price of $1.25. The warrants expire on January 14, 2025.
 
In the three and nine months ended June 30, 2019:
 
On October 2, 2018 in relation to the follow-on firm commitment underwritten offering, we issued to the representative of the underwriters warrants to purchase in aggregate 51,429 shares of common stock with an exercise price of $4.375. The warrants expire on September 28, 2023.
 
In May 2019 in relation to the secondary offering, we issued to the selling agent warrants to purchase in aggregate 60,000 shares of common stock with an exercise price of $7.50. The warrants expire on May 15, 2024.
 
The following table summarizes the inputs used for the Black-Scholes pricing model on the warrants issued in the nine months ended June 30, 2020 and 2019:
 
 
 
  2020
 
 
  2019
 
Exercise price
 $1.25-$3.9125  
 $4.375-$7.50 
Risk free interest rate
  1.48%-1.63
  2.15%-2.90%
Volatility
  95.36-96.85%
  70.61%-75.03%
Expected term
  5 years  
  5 years  
Dividend yield
  None 
  None 
 
NOTE 11 – STOCK-BASED COMPENSATION
 
Equity Compensation Plan – On June 2, 2015, the Board of Directors of the Company approved the 2015 Equity Compensation Plan (“Plan”). The Plan made 1,175,000 common stock shares, either unissued or reacquired by the Company, available for awards of options, restricted stocks, other stock grants, or any combination thereof. The number of shares of common stock available for issuance under the Plan shall automatically increase on the first trading day of our fiscal year during the term of the Plan, beginning with calendar year 2016, by an amount equal to one percent (1%) of the total number of shares of common stock outstanding on the last trading day in September of the immediately preceding